TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06071182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Task-oriented Fruit ninja game
Description: The fruit ninja game were played from tablet PC 20 minutes in a day and 2 times in a week for 4 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham-controlled therapy
Description: The fruit ninja game playing video (https://www.youtube.com/watch?v=cAb0cAviA1s) was watched on the same tablet for 3 minutes a day, twice a week, for 4 weeks, and the wrist and wrist exercises were repeated for 2 minutes on a flat and smooth table. movements were made.
Study: NCT03643367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Included patients, randomized in experimental group, intravenous sedation will be interrupted and followed by a 4 hour sedation with the volatile anesthetic sevoflurane.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Included patients randomized in control group, intravenouse sedation is continued with propofol
Study: NCT05531448

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: two way texting
Description: Automated 2WT-based adherence support messages combined with scheduled visit reminders focus on preventing visit default will be implemented. One-way blast motivational support messages will be sent to all new ART patients who opt-into 2WT. ART visit reminders 3- and 1- day before visits will ask clients to respond with 1=attend and 0=no, triggering 2wT responses to clients to reschedule visits, record transfers, etc. 2WT clerks proactively communicate with clients before a visit to prevent default or ascertain true outcomes for those who don't return. Those who miss visits receive additional 2wT reminders. On day 14 post visit, 2wT patients who missed visits, did not respond to text or did not have outcomes updated (transfer, stop, etc.), are identified by the 2WT system and referred to B2C for tracing, days or months earlier than routine B2C. The 2wT-generated tracing list is more timely and accurate, reducing workload and increasing B2C effectiveness
Study: NCT06479551

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high intensity-low volume resistance training
Description: 13 participants will be in experimental group giving them High intensity-low volume resistance training protocol of 4 reps and 2 sets comprising 90% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity-high volume resistance training
Description: 13 participants will be in control group giving them Moderate intensity-high volume resistance training of 8 reps and 3 sets comprising 80% of 1 RM parallel back squats for six weeks measure all values before giving them protocol and after protocol.
Study: NCT06095154

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CTV Delineation Based on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
Description: CTVp2 is generated by expanding GTVp by 10 mm and including the nasopharyngeal mucosa.
Study: NCT06640998

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Matrix Pro
Description: Study subjects received up to three (3) study treatments with the Matrix Pro applicator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Matrix Pro
Description: Study subjects received up to three (3) study treatments with the Matrix Pro applicator
Study: NCT06639698

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diosgenin
Description: Patients will take a tablet containing diosgenin (120 mg), alpha-lactalbumin (100 mg) and vitamin D (50 mcg) - two times per day for six months
Study: NCT04645953

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 3mg AZ-010
Description: Subject will receive a single inhaled dose (3mg)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 1mg AZ010
Description: Subject will receive a single inhaled dose (1mg)

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Staccato Placebo
Description: Subject will receive a single inhaled dose (Staccato Placebo)
Study: NCT05319002

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group EMDR
Description: The eight phases of the adapted group EMDR protocol was administered during each session: 1. Meeting: Explaining the nature of trauma, group rules, name tags, filling in the scales. 2. Preparation: Exploring children's support system, explaining EMDR, safe place, resource exercise, and installation with bilateral stimulation (BLS, butterfly hug or knee tapping). 3. Assessment: Drawing the worst image on a small separate sheet of paper, SUD level, (negative cognition, emotions, body sensations - if possible). 4. Desensitization: It is done with drawing on 4 separate papers with BLS (butterfly hug or knee tapping). 5. Installation: With the healing story written according to the adaptive information processing (AIP) model, the installation is accompanied BLS. 6. Body scan: A positive body state is installed with the relaxation technique. 7. Closure \& future template: Strong closure with artwork. 8. Re-evaluation: if possible.
Study: NCT05131711

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined stereotactic radiosurgery and enhanced immunotherapy
Description: Patients will be administrated immunal adjuvants intratumorally and systemically with concurrent stereotactic radiosurgery.
Study: NCT05199441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroxydibutylether group
Description: This group takes 1.500 mg/day of dihydroxydibutylether for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group placebo
Description: This group takes 1,500 mg/day of placebo for 8 weeks.
Study: NCT04165525

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: comparison of using an argon gas and high frequency electrical current ablation device with a standard Bovie electrosugical device without argon gas.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: comparison of using an argon gas and high frequency electrical current ablation device with a standard Bovie electrosugical device without argon gas.
Study: NCT05513950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHF10067 starting dose
Description: Intravenous administration of a starting dose of the monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHF10067 intermediate dose
Description: Intravenous administration of an intermediate dose of the monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CHF10067 high dose
Description: Intravenous administration of a high dose of the monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of a physiological solution as placebo.
Study: NCT05060237

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BF-200 ALA and red light LED lamp
Description: Photodynamic therapy (PDT) using BF-RhodoLED® XL (ALA-PDT, Ameluz®-PDT):~Topical application of 3 tubes BF-200 ALA on the expanded treatment field (60 cm²), followed by red light illumination with BF-RhodoLED® XL after 3 h incubation of study medication under light-tight, occlusive dressing.
Study: NCT05418868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir 200 mg/mL
Description: CAB 200 mg/mL will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir >=400 mg/mL
Description: CAB \>=400 mg/mL will be administered by IM or SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir >=400 mg/mL
Description: CAB \>=400 mg/mL will be administered by IM or SC injection.
Study: NCT05531305

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle ultrasound
Description: Standardized ultrasonographic measurement of quadriceps muscle layer thickness.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indirect calorimetry
Description: Non-invasive measurement of resting energy expenditure using the Q-NRG metabolic monitor with hood and canopy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hand dynamometry
Description: Assessment of handgrip strength using hand dynamometry.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRC Sum Score
Description: Assessment of muscle function/limb strength using the Medical Research Council sum score (12-60 points).
Study: NCT05659511

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI data was acquired with a GE discovery MR750 3.0 T scanner using an eight-channel phased- array head coil. Foam padding was used to restrict head movement and ear plugs were used to eliminate scanner noise. During the acquisition period, all participants were asked to keep their eyes closed and not to think anything.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI data was acquired with a GE discovery MR750 3.0 T scanner using an eight-channel phased- array head coil. Foam padding was used to restrict head movement and ear plugs were used to eliminate scanner noise. During the acquisition period, all participants were asked to keep their eyes closed and not to think anything.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI data was acquired with a GE discovery MR750 3.0 T scanner using an eight-channel phased- array head coil. Foam padding was used to restrict head movement and ear plugs were used to eliminate scanner noise. During the acquisition period, all participants were asked to keep their eyes closed and not to think anything.
Study: NCT01825083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine group receives 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9 % normal saline group receives same volume as the ketamine dose
Study: NCT05278338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT103
Description: subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT103
Description: subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT103
Description: subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection, once every 6 months (Q6M), with a total of 2 administrations
Study: NCT05044949

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The study product is a probiotic strain

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: The study product is a probiotic strain

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study product is a placebo to the probiotic strain
Study: NCT05309473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips SmartSleep Acoustic Stimulation Device
Description: Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive acoustic stimulation during the four hours of sleep.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham (no Acoustic Stimulation)
Description: Prior to bedtime on the first two recovery nights, a Philips SmartSleep device will be applied to the head of each subject. Subjects will receive Sham (no acoustic stimulation) during the four hours of sleep.
Study: NCT06090617

Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: Skin biopsies were obtained in all recruited patients.

Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: Skin biopsies were obtained in all recruited patients.

Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: Skin biopsies were obtained in all recruited patients.

Intervention type: PROCEDURE
Intervention: Skin Biopsy
Description: Skin biopsies were obtained in all recruited patients.

Intervention type: PROCEDURE
Intervention: Video-laparoscopic adrenalectomy
Description: Video-laparoscopic adrenalectomy in those with unilateral PA. (PA group 1)
Study: NCT04895813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: The patient will be given pre-colonoscopy training and guidance by telephone.
Study: NCT06047600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uroconnect Follow Up Group
Description: Inplementation of UroConnect remote monitoring Medical Device (DM) to optimize patient support and nursing coordination.
Study: NCT05502991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus Bevacizumab
Description: 200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab plus Bevacizumab
Description: 200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks
Study: NCT06455124

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Shor-course radiotherapy: 25Gy/5Fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: PD-1 antibody (Toripalimab): 240mg d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 d1-14 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2 d1 q3w
Study: NCT05418868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Formulation I
Description: CAB Formulation I will be administered by IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: rHuPH20 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: rHuPH20 will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV
Description: RPV will be administered by IM injection.
Study: NCT05882344

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device Implantation- Boston Scientific, VERCISE GENUS™ system
Description: Participants will be implanted with DBS leads bilaterally, targeting the Nucleus Basalis of Meynert. The study team will record Local Field Potentials with and without stimulation, intraoperatively. These results will help the team determine at the end of the study whether LFP desynchronization (decrease in 5-15 Hz power), or other physiological signature, can be used to predict the location that provides the most effective intervention. Finally, the team will also ascertain the safety of the procedure and NB stimulation itself.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DBS Stimulation - Boston Scientific, VERCISE GENUS™ system
Description: Daily intermittent stimulation (60 Hz x 20s/min)
Study: NCT05110521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROMPTS
Description: PROMPTS is a two-way Short Message Service (SMS) digital health platform that connects mothers with information, advice and referrals to care during the prenatal and postnatal period. The platform also collects information from women on care experience that is reported back to maternity facilities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MENTORS
Description: MENTORS is a program in which in facility nurse-mentors are trained and supported to offer training to nurses, midwives and other maternity facility staff on aspects of basic and emergency obstetric and newborn care.
Study: NCT05913583

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Immune checkpoint inhibitors work by blocking checkpoint proteins from binding with their partner proteins. This prevents the off signal from being sent, allowing the T cells to kill cancer cells.One such drug acts against a checkpoint protein called CTLA-4. Other immune checkpoint inhibitors act against a checkpoint protein called PD-1 or its partner protein PD-L1.
Study: NCT05753241

Intervention type: OTHER
Intervention: no intervention
Description: It's only observational study. No interventions.

Intervention type: OTHER
Intervention: no intervention
Description: It's only observational study. No interventions.

Intervention type: OTHER
Intervention: no intervention
Description: It's only observational study. No interventions.
Study: NCT05165199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat 10mg
Description: Patients of chronic constipation with loss of defecation desire are administered Elobixibat 10mg for 4 weeks
Study: NCT04108988

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: InvestiDate
Description: Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Health Related Video Game
Description: Participants will be randomly assigned to play either InvestiDate (n=40), or the non-health related attention and time control condition multiplayer videogame (n=40).
Study: NCT04376333

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Treatment
Description: Cognitive-behavioral coping skills training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Assessment and Treatment Program
Description: Experience-sampling based cognitive behavioral coping skills assessment and training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Conservative Care
Description: Standard conservative dental care for orofacial pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Conservative Care
Description: Standard conservative dental care for orofacial pain
Study: NCT06435741

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-3PRGD2 Spect-CT scan
Description: Before the operation，SPECT-CT imaging of lymph nodes was performed by integrin αvβ3-specific 99mTc-3PRGD2 probe. The locations of 99mTc-3PRGD2 SPECT-CT were determined by preoperative CT scan. During the operation, D2 lymph node dissection of gastric cancer was performed under the guidance of fluorescent laparoscopy。
Study: NCT05600283

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Swab kit (COBAS HPV 4800 Assay -Evalyn brush)
Description: Patient self-sampling swab kit to collect a vaginal sample for HPV testing

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Clinician-collection of cervical sample for HPV testing
Description: Speculum exam and collection of a cervical specimen using standard endocervical brush and spatula placed into ThinPrep medium for HPV testing (Evalyn brush)
Study: NCT05806164

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]
Description: The beta-agonist oral medication will be prescribed and dose adjusted per usual care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA 100 UNT [Botox]
Description: OnabotulinumtoxinA will be prepared by dissolving 100 units into 10 ml of injectable saline. The injection will be an office based procedure, performed per usual care.
Study: NCT05885841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XTR004
Description: At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi~At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi.
Study: NCT06050720

Intervention type: DEVICE
Group type: OTHER
Intervention: Apne-Scan DC1 device
Description: The primary objective of this exploratory study is to assess Apnea-Tech's UKCA Class I Apne-Scan DC1 sleep apnoea screening device in assisting a clinical diagnosis of sleep apnoea in comparison to standard sleep apnoea test devices (ResMed NOX T3 and Phillips Alice Night One).
Study: NCT05866367

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Regular Insulin
Description: Regular insulin administered intranasally at either 40 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Regular insulin
Description: Regular insulin administered intranasally at either 80 IU
Study: NCT05168384

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Extracorporeal Photopheresis
Description: ECP procedures will be performed using a Therakos Cellex integrated, closed photopheresis system (Therakos, Inc., a Mallinckrodt Pharmaceuticals Company).~ECP will administered according to the following schedule (Group A):~Weeks 1-8: Twice per week (16 sessions). Weeks 9-16: Once per week (8 sessions). Weeks 17-24: Once every 2 weeks (4 sessions). Total: 28 sessions (within 24 weeks).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MS standard of care
Description: Disease-modifying Therapy -DMT, recommended by the American Academy of Neurology -AAN

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: MS standard of care
Description: Disease-modifying Therapy -DMT, recommended by the American Academy of Neurology -AAN
Study: NCT05375344

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Group
Description: Home-based exercise group intervention
Study: NCT05814822

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for insomnia (CBTi-CB-TM)
Description: Participants randomized to CBTi-CB-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn cognitive and behavioral strategies for insomnia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene Education (SHE-TM)
Description: Participants randomized to SHE-TM will participate in 6 individual telemedicine sessions delivered by a trained therapist to learn sleep hygiene and educational strategies for insomnia.